

Feeding the AMR Therapeutics Pipeline - JPIAMR Therapeutics Workshop 2021

Day 1 – Tuesday April 20th		
Time (CET)	Session details	Moderators and Speakers
13:00 – 13:05	Welcome from the Chair	Workshop Chair - Marc Lemonnier
13:05 – 13:10	Funder presentation	JPIAMR – Jess Boname
13:10 – 14:40	Session 1 - Antimicrobial Therapeutics Landscape	Moderator - Rafael Canton
13:10 – 13:30	Keynote presentation - AMR Therapeutics Landscape	Ursula Theuretzbacher
13:30 – 14:40	Panel Discussion with Q&A from workshop participants	Alessandra Martini – EC Peter Beyer – WHO Florence Sejourne – BEAM Stefano Messori – OIE/STAR-IDAZ Erin Duffy – CARB-X Graham Somers – GSK IMI Portfolio Director Laura Marin – JPIAMR Tim Jinks – Wellcome Trust
14:40 – 14:50	Break	
14:50 – 15:50	Session 2 - Choosing wisely — is your product worth developing?	Moderator - John Rex
14:50 – 15:00	Invited speaker	John Rex
15:00 – 15:50	Panel Discussion with Q&A from workshop participants	Kevin Outtersen – CARB-X Laura Piddock – GARDP Camilla Petrycer Hansen – Novo REPAIR Impact Fund Marco Cavaleri – EMA Christine Ardal – representing IMI DRIVE-AB
15:50 – 16:00	Break	
16:00 – 16:50	Session 2a – Activities to support the AMR therapeutics research community	Moderator – Jess Boname

16:00 – 16:10	CF Syndicate in AMR	<u>Jessica Lee</u> ¹ , Paula Sommer ² , Beverley Isherwood ¹ , Lucy Allen ² , Alessandra Gaeta ¹ 1. Medicines Discovery Catapult, UK 2. Cystic Fibrosis Trust, UK
16:10 – 16:20	Pew Evaluates the Global Clinical Pipeline of Antibiotics and Non-traditional Bacterial Products	<u>Cara Lepore</u> , Wes Kim, Katie Prosen, The Pew Charitable Trusts, USA
16:20 – 16:30	South Africa/UK Antimicrobial Drug Discovery Hub	<u>Rosemary Dorrington</u> ^{1*} , Mathew Upton ^{2*} , Hai Deng ³ , Rebecca Goss ⁴ , Karin Jacobs ⁵ , Perry Kaye ¹ , Rui Krause ¹ , Marelize LeRose-Hill ⁶ , Gwynneth Matcher ⁷ , Derek Ndinteh ⁸ , Alex O’Neill ⁹ , Paul Race ¹⁰ , Stephanie van Heerden ¹¹ 1. Rhodes University, SA; University of Plymouth, UK 2. University of Plymouth, UK 3. University of Aberdeen, UK 4. University of St Andrews, UK 5. University of Stellenbosch, SA 6. Cape Penicolid University of Technology, SA 7. South African Institute for Aquatic Biodiversity, SA 8. University of Johannesburg, SA 9. University of Leeds, UK 10. University of Bristol, UK 11. University of Kwazulu-Natal, SA * SA and UK PIs
16:30 – 16:40	iiCONs role in feeding the AMR pipeline	<u>Janet Hemingway</u> , Liverpool School of Tropical Medicine, UK, Peter Jackson, Infex Therapeutics UK, with partners from Evotec UK, Unilever UK, Royal Liverpool and Broadgreen University Hospitals Trust, UK
16:40 – 16:50	10-minute Q&A and with all speakers as panel	
16:50 – 17:00	Short wrap-up from the Workshop Chair	Marc Lemonnier

Day 2 – Wednesday April 21st		
Time (CET)	Session details	Moderators and Speakers
13:00 – 13:05	Opening remarks	Marc Lemonnier
13:05 – 14:15	Session 3 - Mtb antimicrobial pipeline	Moderator - Mirfin Mpundu
13:05 – 13:15	Drug discovery to shorten the duration of chemotherapy	Helena Boshoff, NIAID, USA
13:15 – 13:25	High throughput screening for Mtb therapeutics	Vinayak Singh, University of Cape Town, South Africa
13:25 – 13:35	Pharmacokinetics and pharmacodynamics of anti-tuberculosis agents.	Rada Savic, University of California at San Francisco, USA
13:35 – 13:45	Reviving ethionamide. TRICKy, but possible	Modesto Jesus Remuinan-Blanco, GSK
13:45 – 13:55	Bedaquilin story	Professor Anil Koul, London School of Hygiene and Tropical Medicine and Janssen (UK)
13:55 – 14:15	20 minute Q&A with all speakers as panel	
14:15 – 14:25	Break	
14:25 – 15:35	Session 4 - Novel antimicrobial targets	Moderator - Jordi Vila
14:25 – 14:35	Boosting innate immunity to treat bacterial pneumonia - ABIMMUNE	<u>Jean-Claude Sirard</u> , Institut Pasteur de Lille, France Tom van der Poll, University of Amsterdam, Netherlands Mustapha SI-TAHAR, INSERM, Tours, France Charlotte KLOFT, Freie Universität Berlin, Germany Martin RUMBO, National University of La Plata, Argentina
14:35 – 14:45	Fighting antimicrobial resistant infections by high-throughput discovery of biofilm-disrupting agents and mechanisms - DISRUPT	<u>Morten Kjos</u> , Norwegian University of Life Sciences Nassos Typas, EMBL Heidelberg, Germany Jan-Willem Veening, University of Lausanne, Switzerland Christoph Merten, EMBL Heidelberg, Germany and EPFL Lausanne, Switzerland

14:45 – 14:55	The antibiotic roseoflavin targets flavoproteins and FMN riboswitches - EXPLORE	<u>Matthias Mack</u> , Hochschule Mannheim, Germany Ruth Brenk, Vipul Panchal, U Bergen, Norway Gints Smits, Latvian Institute of Organic Synthesis Daniel Lafontaine, Université de Sherbrooke, Canada
14:55 – 15:05	Novel antimicrobials specific against <i>Helicobacter pylori</i> – FLAV4AMR	<u>Javier Sancho</u> , University of Zaragoza, Spain Eliette Touati, Institut Pasteur, Paris Ulrich E. Schaible, Research Center Borstel, Germany Alain Bousquet-Melou, INRA, ENVT, France
15:05 – 15:15	Sensitising <i>Pseudomonas aeruginosa</i> biofilms to antibiotics and reducing virulence through novel target inhibition - SENBIOTAR	Miguel Cámara, University of Nottingham, UK Peter Nielsen, University of Copenhagen, Denmark Roger Levesque, University of Laval, Canada Christel Bergström, Uppsala University, Sweden <u>Fadi Soukarieh</u> , University of Nottingham, UK
15:15 – 15:35	20-minute Q&A and discussion with speakers as panel	
15:35 – 15:45	Break	
15:45 – 16:55	Session 5 - Non-traditional antimicrobials	Moderator – Richard Gordon
15:45 – 15:55	Development of novel Mycobacterial Tolerance Inhibitors (MTIs) against MDR/XDR tuberculosis - MTI4MDR-TB	<u>Tahira Riaz</u> ² , Siva Krishna Vagolu ² , Souvik Sarkar ¹ , Håvard Homberset ² , Mari Støen ² , Fredrik Almqvist ¹ and Tone Tønjum ² 1. Umeå University, Sweden 2. University of Oslo, Oslo University Hospital, Norway
15:55 – 16:05	Systemically delivered bactericidal antimicrobial peptides to treat bacterial lung infections	<u>James Mason</u> ¹ , Mark Sutton ² , Charlotte Hind ² , Chris Lorenz ¹ , Clive Page ¹ , Simon Pitchford ¹ , Richard Amison ¹ , David Phoenix ³ 1. King's College London, UK 2. Public Health England, UK 3. London South Bank University, UK
16:05 – 16:15	A novel best in class agent for prevention of post-surgical infections - AMPND	<u>Gordon Barker</u> , Amprologix Ltd, UK Ian Fotheringham, Ingenza Ltd, UK Mat Upton, Amprologix Ltd, UK
16:15 – 16:25	Repurposing an antiparasitic as an anti-staphylococcal agent	Sidharth Chopra, <u>Grace Kaul</u> , CSIR-Central Drug Research Institute, Lucknow, India

16:25 – 16:35	Host targeted drug therapy in TB	Sandra Peña-Diaz, Celine Rens, Sahile Henok, Tirosh Shapira, Joseph D Chao, Tom Pfeifer, Clement K.M. Tsui, Flavia Sorrentino, Gagandeep Narula, Abraham Lopez, Adama Bojang, Xingji Zheng, Adrian Richter and Yossef Av-Gay, University of British Columbia, Canada
16:35 – 16:55	20-minute Q&A and discussion with speakers as panel	
16:55 – 17:00	Short wrap-up from the Workshop Chair	Marc Lemonnier

Day 3 – Thursday April 22 nd		
Time (CET)	Session details	Moderators and Speakers
13:00 – 13:05	Opening remarks from the Chair to welcome everyone back and summarise previous day for newcomers (slides from end of day 2)	Marc Lemonnier
13:05 – 14:15	Session 6 - Novel strategies	Moderator - Kyeong Kyu Kim
13:05 – 13:15	Targeting microbial metabolism to combat the AMR in <i>Staphylococcus aureus</i>	<u>Akhilesh K. Chaurasia</u> , Nayab Batool, Kyeong Kyu Kim Sungkyunkwan University School of Medicine, South Korea
13:15 – 13:25	Design, Synthesis and Lead Generation of Novel Siderophore Conjugates for the Detection and Treatment of Infections by Gram-Negative Pathogens - SCAN	Mark Brönstrup, Helmholtz Centre for Infection Research, Germany Isabelle Schalk, CNRS, University of Strasbourg, France Doron Shabat, Tel Aviv University, Israel
13:25 – 13:35	Development of a First-in-Class Antibacterial Drug Using a High-Resolution Computational Model of the Biosynthesis of the Outer Envelope of <i>E.coli</i>	<u>Ajay Mistry</u> , John George, Ed Siegwart, Tony Raynham Oppilotech Ltd, UK
13:35 – 13:45	Antibiotic translocation across bacterial membranes and bacterial susceptibility, concepts & methods - Antabs	Jean-Marie Pages ¹ , Anne Davin ¹ , Jean-Michel Bolla ¹ , Muriel Masi ² , Matthieu Refregiers ² , Paolo Ruggerone ³ , Mathias Winterhalter ⁴ 1. INSERM, Aix-Marseille University, France 2. Synchrotron SOLEIL, Gif-sur-Yvette, France 3. University of Cagliari, Italy 4. JUB, Bremen, Germany
13:45 – 13:55	Developing combinations of CO-ACTIVE antimicrobials and non-antimicrobials – CO-ACTION	<u>Johan Mouton</u> , Joseph Meletiadis, Erasmus University Medical Center, Netherlands Lena Friberg, Thomas Tängdén, Uppsala University, Sweden Françoise Van Bambeke, Université Catholique de Louvain, Belgium William Couet, Université de Poitiers, France Alain Bousquet-Mélou, INRAE, France
13:55 – 14:15	20-minute Q&A and discussion with speakers as panel	

14:15 – 14:25	Break	
14:25 – 15:25	Session 7 - Economic incentives	Moderator - Katherine Payne
14:25 – 14:35	UK antibiotic reimbursement model	Mark Sculpher, Professor of Health Economics, York UK
14:35 – 14:45	Sweden antibiotic reimbursement model	Jenny Hellman, Public Health Agency, Sweden
14:45 – 14:55	Invited speaker - 10 minute presentation	Richard Gold, McGill University
14:55 – 15:05	Invited speaker - 10 minute presentation	Bryan Dean, Association of the British Pharmaceutical Industry
15:05 – 15:25	20 minute Q&A and discussion with speakers as panel members	
15:25 – 15:35	Break	
	Session 8 – Antimicrobial Stewardship, Access and Sustainability	Moderator – Patrick Stewart, Director General, Health Canada
15:35 – 16:00	Keynote presentation with questions – Introduction by Pierre Sabourin, Assistant Deputy Minister, Health Canada	Professor Dame Sally Davies
16:00 – 16:40	Panel Discussion with Q&A from workshop participants	Oliver Williams, Wellcome Trust Yann Ferrisse, GARDP Margo Warren, Access to Medicines Foundation Mirfin Mpundu, ReAct Africa
16:40 – 16:55	Scoping the next JPIAMR call	JPIAMR & Workshop Chair
16:55 – 17:00	Workshop wrap-up	Workshop Chair- Marc Lemonnier, Funders - Jess Boname